Also found in: Dictionary, Thesaurus, Encyclopedia.

antihemophilic factor



(trade name),


(trade name),


(trade name),


(trade name),

factor VIII

(trade name),

Helixate FS

(trade name),

Helixate NexGen

(trade name),


(trade name),


(trade name),


(trade name),

Kogenate FS

(trade name),


(trade name),


(trade name),


(trade name)


Therapeutic: hemostatic agents
Pharmacologic: blood products
Pregnancy Category: C


Management of hemophilia A associated with a deficiency of factor VIII.Humate-P is used in the management of von Willebrand’s disease that has not responded adequately to desmopressin.Humate-P is used for prevention of excessive bleeding during and after surgery in patients with severe von Willebrand's disease.Kogenate FS and Helixate FS are also used for routine prevention to decrease bleeding and risk of joint damage in children with hemophilia A who have no pre-existing joint damage.Advate is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A.


An essential clotting factor required for the conversion of prothrombin to thrombin.

Therapeutic effects

Correction of deficiency states with resultant decreased bleeding.


Absorption: After IV administration, absorption is complete.
Distribution: Rapidly cleared from plasma; does not cross the placenta.
Metabolism and Excretion: Used up in the clotting process.
Half-life: 8.4–19.3 hr (reduced in the presence of inhibitor antibodies and during active bleeding).

Time/action profile (levels of factor VIII)

IVrapid1–2 hr8–12 hr


Contraindicated in: Hypersensitivity to hamster, murine, or bovine proteins (in recombinant and monoclonal antibody products); Hypersensitivity to antihemophilic factor (AHF).
Use Cautiously in: Obstetric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • headache
  • lethargy
  • loss of consciousness
  • sedation

Ear, Eye, Nose, Throat

  • visual disturbances


  • chest tightness
  • hypotension
  • tachycardia


  • nausea
  • vomiting


  • flushing
  • urticaria


  • intravascular hemolysis
  • postoperative hemorrhage


  • back pain


  • paresthesia


  • allergic reactions
  • hepatitis B, C, D, or HIV virus infection (small risk from frequent use of large amounts)
  • chills
  • fever
  • jaundice
  • rigor


Drug-Drug interaction

None significant.


Recommended doses vary from product to product. Consult individual product information for more specific dosing information. Dose may be calculated using the following formula: Dose AHF (units) = body weight (kg) × desired AHF increase (% normal) × 0.5. Each unit of AHF/kg may be expected to produce a 2% rise in factor VIII activityPrevention of Spontaneous Hemorrhage
Intravenous (Adults and Children) 25–40 AHF units/kg (or amount necessary to increase plasma factor VIII levels by 5–30% of normal, depending on situation).
Treatment of Minor Hemorrhage (severe epistaxis, oral mucosal bleeding)
Intravenous (Adults and Children) A single infusion of the amount necessary to increase plasma factor VIII levels by 20–30% (10–15 units/kg) every 8–12 hr for 1–2 days); additional antifibrinolytics needed for oral mucosal bleeding.
Treatment of Moderate Hemorrhage (hemarthroses/hematoma/GI bleeding/retroperitoneal bleeding)
Intravenous (Adults and Children) 15–25 units/kg (or amount necessary to increase plasma factor VIII levels by 30–50% ) every 8–12 hr for 1–2 days (continue for 1–2 days after GI bleeding stops or for at least 3 days following retroperitoneal hematoma).
Treatment of Trauma (without signs of bleeding/tongue or retropharyngeal bleeding)
Intravenous (Adults and Children) 20–25 units/kg (or amount needed to increase plasma factor VIII levels by 40–50%) q 8–12 hr for 2–4 days; additional antifibronlytics needed for tongue/retropharyngeal bleeding.
Treatment of Severe Hemorrhage (trauma with bleeding/intracranial bleeding)
Intravenous (Adults and Children) 50 units/kg (or amount needed to increase plasma factor VIII levels by 100% ) every 8–12 hr for 10–14 days (a continuous infusion of 3 units/kg/hr may also be used).
Management of Perioperative Hemostasis—Major Surgery
Intravenous (Adults and Children) 50 units/kg or amount necessary to raise plasma factor VIII levels to 100% of normal given then 50% of that amount every 8—12 hr to maintain level (a continuous infusion of 3 units/kg/hr may also be used) dosing may be tapered to maintain plasma factor VIII levels of at least 30% of normal for 10–14 days postoperatively; longer period may be required for orthopedic surgery.
Management of Perioperative Hemostasis—Dental or Oral surgery
Intravenous (Adults and Children) 40 units/kg; if antifibrinolytics are used, a single dose may be sufficient.
Treatment of von Willebrand's disease (Humate-P)
Intravenous (Adults and Children) 40–80 units/kg q 8–12 hr; further adjustments made on the basis of laboratory assessment and clinical situation.
Prevention of Postoperative Bleeding in Patients with von Willebrand's Disease
Intravenous (Adults and Children) 60 units/kg initially; then in 30 min with dose based on laboratory assessment and clinical situation. In emergency surgery a loading dose of 50–60 units/kg may be used with subsequent doses based on coagulation factor levels.
Prevention of Bleeding and Joint Damage in Children with Hemophilia A and No Pre-Existing Joint Damage (Kogenate FS and Helixate FS)
Intravenous (Children) 25 units/kg every other day.
Routine Prophylaxis (Advate)
Intravenous (Adults and Children) 20–40 units/kg every other day (3–4 times/week); adjust dose based on clinical response.


Injection: 250 units/vial, 500 units/vial, 750 units/vial, 1000 units/vial, 1500 units/vial, 2000 units/vial, 3000 units/vial

Nursing implications

Nursing assessment

  • Monitor BP, pulse, and respirations. If tachycardia occurs, slow or stop infusion rate and notify health care professional.
  • Obtain history of current trauma; estimate amount of blood loss.
  • Monitor for renewed bleeding every 15–30 min. Immobilize and apply ice to affected joints.
  • Monitor intake and output ratios; note color of urine. Notify health care professional of significant discrepancy or if urine becomes red or orange. Patients with types A, B, and AB blood are particularly at risk for hemolytic reaction.
  • Assess for allergic reaction (wheezing, tachycardia, urticaria, hives, chest tightness, stinging at IV site, nausea and vomiting, lethargy). Diphenhydramine (Benadryl) may be used as a premedication to prevent acute reactions. Stop infusion, notify health care professional.
  • Lab Test Considerations: Monitor plasma factor VIII levels. To prevent spontaneous bleeding, at least 5% of the normal factor VIII level must be present.
    • Obtain baseline and periodic results of CBC, platelet count, direct Coombs’ test, urinalysis, partial thromboplastin time (PTT), thromboplastin generation test, and prothrombin generation test. ↓ hematocrit and ↑ Coombs’ test may indicate hemolytic anemia.
    • Monitor coagulation studies before, during, and after therapy to assess effectiveness of therapy.
    • Patients with ↑ inhibitor levels may not respond or may require ↑ doses.

Potential Nursing Diagnoses

Ineffective tissue perfusion (Indications)
Risk for injury (Indications)


  • Inform all personnel of bleeding tendency. Apply pressure to venipuncture sites for at least 5 min; avoid unnecessary IM injections.
    • Dose varies with degree of clotting factor deficit, desired level of clotting factors, and weight.
    • Obtain type and crossmatch of blood in case a transfusion is necessary.
    • The first dose of AHF is given 1 hr before surgery.
  • Intravenous Administration
  • Administer IV only. Refrigerate concentrate until just before reconstitution. Warm concentrate and diluent (provided by manufacturer) to room temperature before reconstituting. Use plastic syringe for preparation and administration. Use an additional needle as an air vent to the vial when reconstituting. After adding diluent, rotate vial gently until completely dissolved. Solution may vary in color from light yellow to clear with a bluish tint. Do not refrigerate after reconstitution; use within 3 hr. Preparations should be filtered before administration.
  • Rate: Rate is based on patient’s response. Administer at a rate of 2 mL/min. May be given over up to 10 min.
  • Y-Site/Additive Incompatibility: Do not admix or administer in the same line with any other medication or solution.

Patient/Family Teaching

  • Instruct patient to notify health care professional immediately if bleeding recurs. Advise patient to observe for bleeding in gums, skin, urine, stool, or emesis.
  • Inform patient inhibitor formation may occur with treatment of hemophilia A. Advise patient to contact their health care professional if they experience lack of clinical response to Factor VIII replacement therapy; may be manifestation of an inhibitor.
  • Caution patient to avoid products containing aspirin or NSAIDs; they may further impair clotting.
  • Review prevention of bleeding with patient (use soft toothbrush, avoid IM and subcut injections, avoid potentially traumatic activities).
  • Inform newly diagnosed hemophilia patients of the need for hepatitis B vaccine. Advise patient that the risk of hepatitis or AIDS transmission may be diminished by the use of heat-treated, pasteurized, solvent/detergent-treated, or monoclonal antibody preparations. Screening programs should also decrease the risk.
  • Advise patients to consult health care professional prior to travel. While traveling advise patients to bring an adequate supply of AHF based on their current treatment regimen.
  • Advise patient to carry identification describing disease process at all times.

Evaluation/Desired Outcomes

  • Prevention of spontaneous bleeding.
  • Cessation of bleeding.
  • Decrease bleeding and risk of joint damage in children with hemophilia A who have no pre-existing joint damage.
  • Prevention or reduction of frequency of bleeding episodes in adults and children with hemophilia A.


Antihemophilic factor/von Willebrand factor complex Hematology A plasma-derived product for treating Pts with hemophilia A and refractory von Willebrand's disease. See Hemophilia A, von Willebrand's disease.
References in periodicals archive ?
Humate-P contains the high molecular weight of multimers of von Willebrand factor important for correcting the coagulation defect in patients with VWD.
Humate-P is also in indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery.
Specific treatments may include desmopressin acetate to release stored von Willebrand factor; von Willebrand factor replacement therapies, such as Humate-P, Antihemophilic Factor/von Willebrand Factor Complex (Human) Dried, Pasteurized; and oral contraceptives to reduce menstrual bleeding and raise von Willebrand factor in the bloodstream.
Humate-P was used to treat 530 different events (73 surgical, 344 bleeding, 93 "other" and 20 prophylaxis).
These study results highlight the ongoing success we have found with Humate-P.